The proprietary Vn96 technology (US Patent # 8,956,878) is a highly effective and flexible tool for the isolation and purification of pathological exosomes that aims at improving and accelerating molecular diagnostics based on biofluid analysis.
The Vn96 peptide has a high specificity and affinity for canonical heat shock proteins (HSPs) lining the surface of exosomes and other extracellular vesicles (EVs). The ease with which the EVs may be captured from cell culture media and biological fluids using the peptide is unprecedented. This technology is a more efficient and more specific isolation method than current methods based on physical characteristics (density and/or size separations) and multiple antibody affinity-based purifications.
Due to their high content in HSPs, the peptide efficiently isolates EVs derived from cells under stress (ex: cancer, infection, cardiovascular, neurodegenerative and metabolic diseases) in human or animal body fluids. These EVs can then be analysed for their content in specific pathological biomarkers. This method follows the current clinical diagnostic trend for biomarker screening with non-invasive or minimally invasive measures intended for early disease detection.
Vn96 is a cutting-edge platform technology for enhancing and improving the efficacy, specificity and rapidity of a wide array of disease diagnostic, prevention and treatment technologies. Given its peptide nature and possible chemistries, Vn96 is cost effective, highly flexible and adaptable to your products.